Wednesday, October 14, 2026

Fomento Economico Mexicano S.A.B. De C.V. Already 5% Down, Almost One Hour Before The NYSE Open

Fomento Economico Mexicano S.A.B. De C.V. Already 5% Down, Almost One Hour Before The NYSE Open

(VIANEWS) - The NYSE opens in less than one hour and Fomento Economico Mexicano S.A.B. de C.V.'s pre-market value is already 5.81% down.

Fomento Economico Mexicano S.A.B. de C.V.'s last close was $125.28, 12.65% under its 52-week high of $143.43.

The last session, NYSE ended with Fomento Economico Mexicano S.A.B. de C.V. (FMX) jumping 0.6% to $125.28. NYSE slid 0.73% to $17,886.27, following the last session's downward trend on what was a somewhat negative trend exchanging session.

About Fomento Economico Mexicano S.A.B. de C.V.

Fomento Económico Mexicano, S.A.B. de C.V., through its subsidiaries, operates as a bottler of Coca-Cola trademark beverages. The company produces, markets, and distributes Coca-Cola trademark beverages in Mexico, Guatemala, Nicaragua, Costa Rica, Panama, Colombia, Venezuela, Brazil, Argentina, and Uruguay. It also operates small-box retail chain stores in Mexico, Colombia, Peru, Chile, and Brazil under the OXXO name; retail service stations for fuels, motor oils, lubricants, and car care products under the OXXO GAS name in Mexico; and drugstores in Chile, Colombia, Ecuador, and Mexico under the Cruz Verde, Fybeca, SanaSana, YZA, La Moderna, and Farmacon names. In addition, the company is involved in the production and distribution of collers, commercial refrigeration equipment, plastic boxes, food processing, and preservation and weighing equipment; and provision of logistic transportation, distribution and maintenance, point-of-sale refrigeration, and plastics solutions, as well as distribution platform for cleaning products and consumables. Further, it operates small-box retail and food convenience chain stores in Switzerland, Germany, Austria, Luxembourg, and the Netherlands under the k kiosk, Brezelkönig, BackWerk, Ditsch, Press & Books, avec, Caffè Spettacolo, and ok.–) names, as well as pretzels under the Ditsch name. The company was founded in 1890 and is based in Monterrey, Mexico.

Earnings Per Share

As for profitability, Fomento Economico Mexicano S.A.B. de C.V. has a trailing twelve months EPS of $1.13.

PE Ratio

Fomento Economico Mexicano S.A.B. de C.V. has a trailing twelve months price to earnings ratio of 110.87. Meaning, the purchaser of the share is investing $110.87 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.59%.

Yearly Top and Bottom Value

Fomento Economico Mexicano S.A.B. de C.V.'s stock is valued at $125.28 at 09:30 EST, way below its 52-week high of $143.43 and way higher than its 52-week low of $85.66.

Volume

Today's last reported volume for Fomento Economico Mexicano S.A.B. de C.V. is 372132 which is 41.07% below its average volume of 564080.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Fomento Economico Mexicano S.A.B. de C.V.'s EBITDA is 8.38.

More news about Fomento Economico Mexicano S.A.B. de C.V. (FMX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com